- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| Mo | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | LIXTE Biotechnology regains Nasdaq compliance | 2 | Seeking Alpha | ||
| 16.07. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements | 171 | GlobeNewswire (Europe) | PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| 11.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 09.07. | Lixte Biotechnology Holdings, Inc.: New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials | 9 | GlobeNewswire (USA) | ||
| 08.07. | Lixte Biotechnology raises $1.5 million in registered direct offering | 1 | Investing.com | ||
| 08.07. | Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering | 2 | GlobeNewswire (USA) | ||
| 03.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.07. | Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market | 8 | GlobeNewswire (USA) | ||
| 01.07. | Lixte Biotechnology sichert sich 5 Millionen US-Dollar durch Privatplatzierung | 3 | Investing.com Deutsch | ||
| 01.07. | Lixte Biotechnology secures $5 million in private placement | 1 | Investing.com | ||
| 01.07. | Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market | 1 | GlobeNewswire (USA) | ||
| 18.06. | Lixte Biotechnology files to sell 5.26M shares of common stock, warrants | 2 | Seeking Alpha | ||
| 18.06. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| 17.06. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 18.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 2 | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,320 | +7,32 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
| OCUGEN | 0,982 | +10,41 % | Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| MAINZ BIOMED | 1,990 | +2,05 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und CARE schließen Kooperationsvereinbarung für gemeinsames Versorgungskonzept für Krankenkassen | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed und CARE schließen Kooperationsvereinbarung für gemeinsames Versorgungskonzept für Krankenkassen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,680 | +5,00 % | A Look Ahead: Viking Therapeutics' Earnings Forecast | ||
| IMMUNITYBIO | 2,422 | +4,80 % | ImmunityBio's ANKTIVA Gains UK Approval In Bladder Cancer Treatment | ||
| MARINOMED BIOTECH | 19,250 | 0,00 % | BYD, Marinomed Biotech, Börse München - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,365 | -2,68 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| ORAGENICS | 1,440 | +7,87 % | Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development | SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it... ► Artikel lesen | |
| FIBROGEN | 7,620 | -1,68 % | XFRA 1FG0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFIBROGEN INC. NEW... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,016 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| CAPRICOR | 6,010 | +8,29 % | Oppenheimer reiterates Outperform rating on Capricor stock, sees $1B+ sales | ||
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| RADIUS HEALTH | - | - | +850% CVR-Jackpot: Biotech-Tipp Radius Health beschert Anlegern Geldsegen | Der Optionsvoodoo-Chatraum von sharedealsPlus brummte letzte Woche vor Begeisterung, denn ein längst vergessener Trade sorgt für Jubelstürme und prall gefüllte Konten bei den Mitgliedern des Anlegerclubs... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,200 | +3,45 % | Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma | Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive... ► Artikel lesen | |
| SCHOLAR ROCK | 34,400 | +0,58 % | Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress | Submitted apitegromab U.S. Biologics License Application (BLA) for patients with spinal muscular atrophy in January 2025; U.S. launch anticipated in 4Q 2025
Remain on track to submit European Union... ► Artikel lesen |
Das Unternehmen LIXTE BIOTECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,185 (-4,34 %) liegt der Kurs bei 4,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.